Kalaris Therapeutics Inc (KLRS) financial statements and ratios from SEC XBRL: revenue $5.49M (TTM), net margin -1071.3%, revenue growth -4.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $5.49M |
| Net Margin | -1071.3% |
| Revenue Growth (YoY) | -4.3% |
| EPS Growth (YoY) | 541.0% |
| Price / Book | 1.71 |
| FCF Yield | -31.9% |
| Sector P/E (Healthcare) | 21.7 |
KLRS overview · KLRS earnings · KLRS KPIs · KLRS investor relations · KLRS ownership · KLRS peers · KLRS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.